Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco DB Oil Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.63 (market cap $4.49B), while Invesco DB Oil Fund trades at $18.87. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| ACAD | DBO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Energy |
52-Week High | $28.06 | $23.80 |
52-Week Low | $20.06 | $11.98 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DBO trades at $17.34 with a modest 0.35% daily gain amid bearish technical signals. The stock shows mixed momentum with oversold RSI readings but faces strong resistance at $18. Recent oil price volatility driven by Middle East tensions and supply disruptions creates both opportunities and risks for energy sector stocks.
The outlook remains cautious with technical indicators favoring bearish momentum, though oversold conditions suggest potential for near-term stabilization. Investment opportunity exists if geopolitical tensions sustain higher oil prices, but risks include supply growth and demand uncertainty that could pressure energy stocks further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
